Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
Nidanilimab is a humanized monoclonal antibody that targets l1rap, which inhibits downstream signaling and blocks activation of NFkappa-B, thereby potentially inducing antibody-dependent cellular cytotoxicity, leading to decreased proliferation and increased death of tumor cells expressing IL1RAP (NCI Drug Dictionary).
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Nidanilimab + Pembrolizumab||Nidanilimab Pembrolizumab||0||1|